Metastatic Melanoma MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864
Conditions
Sponsors
F. Hoffman-La Roche Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Disease-specific criteria: - Histologically confirmed melanoma with radiologically confirmed brain metastases - Documented BRAFV600 mutation status of melanoma tumour tissue using a validated genetic test - Measurable brain metastases - Prior systemic therapy for metastatic melanoma is allowed with exceptions as detailed in the exclusion criteria - Prior SRT or surgical therapy of = 10 brain metastases is allowed but prior WBRT is not allowed - Adverse effects of all prior systemic or local treatment must have either returned to baseline or become stable and manageable prior to initiation of study treatment General criteria: - Age >= 18 years - Able to comply with the study protocol, in the investigator’s judgment - ECOG Performance Status 3 months - Willing and able to complete health and quality of life questionnaires required by the protocol - Adequate hematologic and end-organ function - Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use two effective forms of contraception during the course of this study and for at least six months after completion of study therapy - Male patients must agree to refrain from donating sperm for at least six months after the last dose of cobimetinib Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60
Exclusion criteria
Exclusion criteria: Cancer-related criteria: - Ocular melanoma - Leptomeningeal involvement - Uncontrolled tumour-related pain - Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days - Prior WBRT treatment for CNS disease - Increasing corticosteroid dose during the seven days prior to initiation of study treatment or current dexamethasone or equivalent dose of > 8 mg/day - Prior treatment with a BRAF or MEK inhibitor - For patients assigned to Cohort 1 only: prior immunotherapy in the metastatic setting is not allowed. Prior immunotherapy is allowed in the adjuvant setting, provided it is completed >= 90 days prior to study treatment initiation For patients assigned to Cohort 2 only: prior immunotherapy in either the adjuvant or metastatic setting is not allowed - Major surgical procedure other than for diagnosis within four weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study - Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or to any formulation component of cobimetinib or atezolizumab or, for patients assigned to Cohort 2 only, vemurafenib - Any anti-cancer therapy, including chemotherapy, hormonal therapy and radiotherapy, within two weeks prior to initiation of study treatment - Patients assigned to Cohort 2 only: Concomitant treatment with anticonvulsants other than gabapentin, vigabatrin and levetiracetam - Patients assigned to Cohort 2 only: acetaminophen is prohibited within seven days prior to initiation of study treatment unless the patient has an absolute contraindication to the use of non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin - Active malignancy (other than melanoma) or a prior malignancy within the past three years General criteria: - Known risk factors for ocular toxicity - History of clinically significant cardiac dysfunction - Inability to swallow medications - Malabsorption condition that would alter the absorption of orally administered medications - Traumatic injury within two weeks prior to initiation of study treatment - Prior allogeneic stem cell or solid organ transplantation - Active or history of autoimmune disease or immune deficiency - History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan - Uncontrolled diabetes or symptomatic hyperglycaemia - Any Grade>= 3 haemorrhage or bleeding event within 28 days of study treatment initiation - History of stroke, reversible ischemic neurological defect, or transient ischemic attack within six months prior to study treatment initiation - Positive human immunodeficiency virus (HIV) test at screening - Hepatitis B virus (HBV) infection (chronic or acute) - Active hepatitis C virus (HCV) infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: - To evaluate intracranial ORR with cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma as assessed by an IRC - To evaluate intracranial ORR with cobimetinib plus atezolizumab and vemurafenib in BRAFV600 mutation-positive melanoma as assessed by an IRC ; Secondary Objective: - To evaluate the efficacy of cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma with CNS metastases - To evaluate the efficacy of cobimetinib plus atezolizumab and vemurafenib in BRAFV600 mutation-positive melanoma with CNS metastases - To evaluate the safety of cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma with CNS metastases - To evaluate the safety of cobimetinib plus atezolizumab and vemurafenib in BRAFV600 mutation-positive melanoma with CNS metastases ;Primary end point(s): Intracranial objective response rate (ORR);Timepoint(s) of evaluation of this end point: Up to 48 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: Up to 48 months; Secondary end point(s): 1. Extracranial ORR 2. Overall ORR 3. Intracranial, extracranial and overall progression-free survival (PFS) 4. Intracranial, extracranial and overall duration of response (DOR) 5. Intracranial, extracranial and overall disease control rate (DCR) 6. Overall survival 7. Time from study treatment initiation to cognitive symptom deterioration 8. Time from study treatment initiation to symptom and function deterioration 9. Duration of Stable/Improved health-related quality of life (HRQoL) scores 10. Occurrence and severity of adverse events, with severity determined according to NCI CTCAE v4.0 11. Change from baseline in targeted vital signs 12. Change from baseline in targeted clinical laboratory test results | — |
Countries
Brazil, France, Hungary, Italy, Latvia, Spain
Contacts
Public ContactTrial Information Support Line-TISL
F.Hoffmann-La Roche Ltd.
Outcome results
None listed